Agilent Builds Cancer Diagnostics Biz Via Dako Acquisition For $2.2 Billion
This article was originally published in The Gray Sheet
Executive Summary
Research and testing product maker Agilent gains Dako’s c-Kit pharmDx and HER2 FISH pharmDx assays, among other cancer diagnostics, in the firm’s largest acquisition to date.